Latest news with #BostonScientificCorp
Boston Globe
6 days ago
- Health
- Boston Globe
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Marlborough-based Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. Advertisement In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. Advertisement As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading.
CNBC
24-07-2025
- Business
- CNBC
This health care stock forming a 'big base breakout' is ready to separate from the pack, charts indicate
While the health care sector has been a chronic underperformer in recent years, our process is showing that a number of stocks in this struggling sector are exhibiting real signs of strength. With an encouraging earnings report this week, followed by an impressive breakout above resistance, Boston Scientific Corp. (BSX) may be setting up for significant gains beyond current levels. The daily chart shows how BSX is setting up with a classic "big base breakout" pattern, where a multi-month consolidation pattern is finally exited with a significant upside move. As legendary technical analyst Alan Shaw used to say, "The bigger the base, the higher in space!" So after six months of sideways price action, including a test of the 200-day moving average at the April low, BSX appears to be completing a bullish rotation above resistance around $106.50. In terms of upside price targets after a breakout of this magnitude, a common technique is to take the height of the consolidation pattern and project that range to the upside. Given the range of around $20 for this pattern, that would imply a minimum upside objective around $126, representing about a 17% gain from current levels. To further validate this breakout scenario, we can analyze volume indicators to determine whether there is enough buying power represented in the charts. Here we're showing Boston Scientific along with three volume indicators. First, we have the raw daily volume readings, shown just below the daily price bars. Then we are showing the Accumulation/Distribution Line, which represents the trend in volume over time. Finally, we've included the Chaikin Money Flow, which uses daily price and volume movements to measure periods of accumulation and distribution. We can see that Wednesday's rally after the earnings release was marked by about double the normal volume. This shows that significant demand was seen for Boston Scientific as investors literally bought into the bullish case for future earnings growth. The Accumulation/Distribution Line has been trending higher for most of the last 12 months, and the Chaikin Money Flow remains firmly above the zero level. These two technical indicators suggest that BSX is in a period of accumulation, suggesting a bullish outlook with further upside potential. The weekly chart shows that the consolidation from the last six months has indeed represented a brief pause within a multiyear rally phase for Boston Scientific. Since a key breakout above resistance in early 2023, BSX has remained in a consistent uptrend phase with improving relative strength. Two major pullbacks during the uptrend phase, in October 2023 and March 2025, saw this health care name find support at an ascending 40-week moving average. So while BSX has underperformed the S & P 500 in recent months, the long-term trend remains on solid footing. Many investors have been ignoring the health sector in 2025, given the chronic underperformance and questionable technical configurations. But charts like BSX provide an important reminder that even the most chart-challenged sectors can often include stocks that stand out with bullish setups. -David Keller, CMT DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
23-04-2025
- Business
- Yahoo
Is Boston Scientific Corp. (NYSE:BSX) the Best Stock Under $100 to Buy According to Hedge Funds?
We recently published a list of the 12 Best Stocks Under $100 to Buy According to Hedge Funds. In this article, we are going to take a look at where Boston Scientific Corp. (NYSE:BSX) stands against other stocks under $100 to buy according to hedge funds. On April 21, Chris Davis of Davis Advisors appeared on 'The Exchange' on CNBC to talk about selectivity in today's market. Davis pointed out that putting companies in groups like the MAG7 covers their underlying businesses, which can have different fundamentals and therefore prospects. For this reason, he acknowledged that he owns certain stocks from MAG7 but not all. Davis also clarified that his overall focus is on value and growth, which leads him to a diverse set of holdings and not just tech, such as financials and healthcare names. He then argued that the market is shifting back toward selectivity and active management. He suggested that active management is positioned for a resurgence because the indexes have become highly concentrated and richly valued. Davis acknowledged that while he cannot predict the market's short-term movements, the present environment is ideal for stock pickers who can identify resilient businesses that are trading at reasonable valuations. He sees this as an opportunity for active management to outperform, as investors move away from momentum-driven index investing toward a more selective approach. He noted the growing popularity of actively managed ETFs as evidence that investors are beginning to act on this shift away from index concentration. He also believes that within the MAG7, only a few companies are truly well-positioned. Similarly, within the S&P 500, only 5% to 10% of companies possess the resiliency and durability needed for such volatile times. Davis laid out what he sees as the major transitions shaping the current investment environment. First, he described the shift from nearly 15 years of free money to a more normal interest rate environment. Second, he pointed to the end of a multi-decade era of globalization, which was replaced by deglobalization, rising nationalism, and geopolitical tensions. Third, he highlighted the impact of AI. He said that these transitions are occurring against a backdrop of market complacency, with high valuations and concentrated growth expectations. We first used the Finviz stock screener to compile a list of the top stocks that were trading under $100 as of April 22. We then selected the 12 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey's database which tracks the moves of over 1000 elite money managers. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A surgeon examining a patient's brain in an operating room, paramedics nearby. Share Price as of April 22: $93.58 Number of Hedge Fund Holders: 96 Boston Scientific Corp. (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties. It operates in two segments: MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, urological conditions, and neurological movement disorders. In Q4 2024, the company's Electrophysiology sales surged by 172% year-over-year, while for the full year 2024, this segment was up 139%. This is attributed to the continued and rapid adoption of the company's FerraPulse Pulsed Field Ablation system, which has become a transformative technology in the Atrial Fibrillation (AFib) market. FerraPulse surpassed $1 billion in global revenue in 2024 and is treating more than 200,000 patients. Boston Scientific Corp. (NYSE:BSX) is building clinical evidence for FerraPulse, which is highlighted by positive initial results from the ADDvantage AF trial (for evaluating the safety and effectiveness of the system). An updated label for persistent AF is expected in H2 2025, and enrollment for the Avantgarde trial (FerraPulse as a first-line treatment) is almost complete. Data for FerraPoint is expected in H1 2025, with potential FDA approval by year-end. Janus Henderson Enterprise Fund stated the following regarding Boston Scientific Corporation (NYSE: BSX) in its Q2 2024 investor letter: 'Medical device company Boston Scientific Corporation (NYSE:BSX) was another contributor. The stock rose on excitement over the company's U.S. launch of FARAPULSE, a state-of-the-art pulsed field ablation system that treats atrial fibrillation with less damage to surrounding tissues relative to previous therapies. Boston Scientific is currently the only provider of this technology, which taps into a large and growing addressable market. Even beyond our excitement around FARAPULSE, we continue to like Boston Scientific for its diversified product portfolio, which has provided many potential drivers of revenue growth.' Overall, BSX ranks 9th on our list of the best stocks under $100 to buy according to hedge funds. While we acknowledge the growth potential of BSX, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BSX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Washington Post
05-02-2025
- Business
- Washington Post
Boston Scientific: Q4 Earnings Snapshot
MARLBOROUGH, Mass. — MARLBOROUGH, Mass. — Boston Scientific Corp. (BSX) on Wednesday reported fourth-quarter earnings of $566 million. The Marlborough, Massachusetts-based company said it had net income of 38 cents per share. Earnings, adjusted for amortization costs and asset impairment costs, were 70 cents per share. The results exceeded Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of 65 cents per share.
